Sarria Gustavo R, Berenguer Francés Miguel Ángel, Linares Galiana Isabel
Radiotherapy Department, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
Universitätsklinikum Mannheim, Klinik für Strahlentherapie und Radioonkologie, Germany.
Rep Pract Oncol Radiother. 2019 Jan-Feb;24(1):65-67. doi: 10.1016/j.rpor.2018.10.003. Epub 2018 Nov 15.
Amongst all efforts for improving oncological management outcomes, nanoparticles enhanced radiation for breast cancer patient's treatment is a novel approach that has grown interest for research in the last decade. Multiple preclinical data has been published, from all around the globe; however, clinical evidence is still insufficient for implementing the method in routine practice and in disease specific management. Gold nanoparticles (AuNP), which may be among the most studed materials, account for the majority of available data; however, some new materials have also been used in preclinical settings. Without any safety data available at the moment to support an active use, dosimetric and information seems to be consistent with a very promising and hopeful panorama for clinical applications. This review evaluates existing dosimetric data in breast cancer tissue, and a probable future impact in treatment choices and patient outcomes, as further investigation is required in a clinical setting.
在所有改善肿瘤治疗效果的努力中,纳米颗粒增强放疗用于乳腺癌患者治疗是一种新方法,在过去十年中引发了研究兴趣。全球已发表了多项临床前数据;然而,临床证据仍不足以在常规实践和疾病特异性管理中应用该方法。金纳米颗粒(AuNP)可能是研究最多的材料之一,占现有数据的大部分;不过,一些新材料也已用于临床前研究。目前尚无任何安全数据支持积极应用,剂量学和信息似乎与临床应用的非常有前景和充满希望的前景一致。本综述评估了乳腺癌组织中的现有剂量学数据,以及对治疗选择和患者预后可能产生的未来影响,因为在临床环境中还需要进一步研究。